Literature DB >> 2417162

Human cellular immune response to copolymer I and myelin basic protein.

J Burns, L J Krasner, F Guerrero.   

Abstract

Copolymer I (Cop I) is being tested as a treatment for MS because it protects animals against experimental allergic encephalomyelitis, and because there is immunologic cross-reactivity reported between Cop I and myelin basic protein (MBP). From the peripheral blood mononuclear cells of four normal individuals, we isolated helper-phenotype T-cell lines that reacted in vitro with Cop I or MBP. Cop I-reactive cell lines did not respond to MBP, nor did MBP-reactive T-cell lines respond to Cop I. Antigen-specific immune tolerance was induced in MBP-reactive cell lines by exposure to MBP in vitro, but similar exposure to Cop I did not induce tolerance in the MBP-reactive cell lines. We found no evidence of immunologic cross-reactivity between Cop I and MBP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2417162     DOI: 10.1212/wnl.36.1.92

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.

Authors:  D Teitelbaum; R Aharoni; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

3.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 5.  The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Authors:  Anne Lise K Hestvik
Journal:  Toxins (Basel)       Date:  2010-04-22       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.